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Abstract
MECP2mutations cause a number of neurological disorders of which Rett syndrome (RTT)
represents the most thoroughly analysed condition. ManyMecp2mouse models have been
generated through the years; their validity is demonstrated by the presence of a broad spec-
trum of phenotypes largely mimicking those manifested by RTT patients. These mouse
models, between which the C57BL/6Mecp2tm1.1Bird strain probably represents the most
used, enabled to disclose much of the roles of Mecp2. However, small litters with little viabil-
ity and poor maternal care hamper the maintenance of the colony, thus limiting research on
such animals. For this reason, past studies often usedMecp2mouse models on mixed
genetic backgrounds, thus opening questions on whether modifier genes could be responsi-
ble for at least part of the described effects. To verify this possibility, and facilitate the main-
tenance of the Mecp2 colony, we transferred theMecp2tm1.1Bird allele on the stronger CD1
background. The CD1 strain is easier to maintain and largely recapitulates the phenotypes
already described inMecp2-null mice. We believe that this mouse model will foster the
research on RTT.
Introduction
Mutations in the X-linkedMECP2 gene (methyl-CpG-binding protein 2) cause a large spec-
trum of neurological disorders affecting almost 1 of 4000 individuals worldwide. Rett syn-
drome (RTT) was the first identified and certainly the most thoroughly characterizedMECP2-
related disease [1,2]. RTT is a devastating genetic disorder that affects primarily young girls
and represents the most common genetic cause of severe intellectual disability in females. RTT
is usually characterized by a severe regression phase occurring between 12 and 18 months of
age that leads to the loss of most, if not all, the previously acquired skills. Clinical symptoms
include impaired cognitive and motor abilities, communication dysfunctions, breathing abnor-
malities, seizures, social withdrawal, hypotonia, scoliosis and stereotypic hand movements. So
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far, more than 500 different RTT-causing mutations have been identified, including missense,
nonsense, frameshift mutations and deletions (catalogued at http://mecp2.chw.edu.au). It is
generally assumed that these mutations cause the loss of Mecp2 functions [3].
The generation of several mouse models carrying differentMecp2mutations has been
instrumental to improve our comprehension of MeCP2 roles and the mechanisms underlying
MECP2-opathies [4,5]. Transgenic animals have also demonstrated that RTT like features in
mice are not irreversible and that part of these defects can be rescued even at late stages of
disease progression [6]. Such results, confirmed by several other studies [7–9], have further
boosted the necessity of usingMecp2mouse models both for basic and preclinical studies.
Currently, three RTT mouse models are predominantly used. Two of them, both generated
in 2001, areMecp2-null animals [10,11]. The laboratory of Adrian Bird produced the
Mecp2tm1.1Bird strain on a C57BL/6 background, removing exons 3 and 4 of theMecp2 gene,
therefore deleting all the coding portion but the first eight N-terminal amino acids [10].
Rudolph Jaenisch and his collaborators developed a null model on a mixed genetic background
(129, C57BL/6 and BALB/c) devoid only of exon 3, therefore including most (116 residues) of
the Methyl-CpG-Binding Domain of the protein. The presence of Mecp2 peptides smaller than
the full-length protein has been described in this animal [11]. A strain expressing a truncating
mutation often found in RTT was generated in 2002 (Mecp2308, [12]). Importantly, all these
mice develop symptoms that recapitulate very well many RTT features. In the male progeny of
each line, the onset of several neurological impairments follows an apparently normal develop-
ment typically lasting 3–5 weeks after birth; death occurs 2–4 weeks later. Symptomatic hemi-
zygous males show reduced movements, abnormal gait, hind limb clasping, reduced weight,
tremors and poor general conditions [10,11,13,14]. Of note, givenMecp2-null male mice are
sterile, null females cannot be generated;Mecp2+/- heterozygous females are therefore neces-
sary to maintain the colony. Females are characterized by a late manifestation of overt symp-
toms, generally appearing between 3 and 6 months of age [10,11]. Because of the faster
appearance of pathological features, the male model has been vastly preferred.
Due to its early commercial availability, the C57BL/6Mecp2tm1.1Bird strain probably repre-
sents the most widely used mouse model of Mecp2 functions and Rett syndrome. This model
displays such a wide number of harsh symptoms that it is often quite hard to distinguish
between those directly ascribable to the absence of Mecp2 and those that are, instead, conse-
quence of the poor condition of the animal. Interestingly, the null phenotype tends to progres-
sively deteriorate as the colony ages, possibly hardening the ability to directly link specific
features to the absence of Mecp2 and not to the general health status of the animal. Accord-
ingly, rearing these animals is quite challenging, especially considering pre-clinical studies that
require large cohorts of mice [15]. In fact, heterozygous dams frequently cannibalize their rela-
tively small litters and progressively take less care of their progeny along with colony aging,
which can obviously have detrimental effects on the phenotype the progeny will develop. In
fact, it is well demonstrated that maternal deprivation in early post-natal development leads to
neuroplasticity defects later in adulthood [16,17]. Through the years some housing methods
have been suggested to facilitate the management of the colony; for example, it is suggested to
supplement cages of pregnant females with irradiated sunflower seeds and face them towards
the light source. Moreover, a good practice is to limit stressful cage maintenance procedures
both before and after delivery. Eventually, it is preferred to always mateMecp2-heterozygous
females with the same male [15]. All these suggestions appear only modestly helpful and are
used only by certain groups not on a regular basis. To ameliorate such poor conditions,
researchers have often transferred the mutant allele on different genetic backgrounds, such as
129/C57BL6, F1 hybrid (i.e. FVB.129F1; 129.B6F1) or even mixed F1 (129S1/SvImJ females
crossed with B6/CBA males) [18–21]. However, the genetic background could affect the
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phenotype; indeed, only in the C57BL/6 backgroundMecp2-null mice exhibit reduced weight
[10, 11]. Verifying whether the defects described in each study could be ascribable to the lack
of Mecp2 itself rather than to the possible roles played by different modifier genes would thus
be highly informative.
We hypothesized that by transferring theMecp2tm1.1Bird genetic modification on the outbred
CD1 (ICR) genetic background [22], we could both simplify the management of the colony and
highlight the influence of the background on some of the RTT like phenotypes. CD1 mice are in
fact characterized by a significant robustness and by the ability to produce large litters [22].
Therefore, as mainly instructed by references 6 and 16, we have examined the general breed-
ing properties of the CD1 line and its symptoms over time. Furthermore, we have assessed
whether molecular, neuronal and behavioural phenotypes that characterize theMecp2-null
mice are maintained in the new genetic background.
Materials and Methods
Animals
TheMecp2-null mouse strain was originally purchased from Jackson Laboratories (B6.129P2
(C)-Mecp2tm1.1Bird/J); this strain was generated on a C57BL/6 background [10]. We crossed
C57BL/6Mecp2 heterozygous females with CD1 wt male mice (Crl:CD1(ICR); Charles River)
and kept backcrossing each generation of CD1 heterozygous females with new CD1 males.
This backcrossing strategy is now well above the 10th generation. All animals were kept in our
on site animal room and daily checked for general health conditions. All procedures were per-
formed in accordance with the European Community Council Directive 86/609/EEC for care
and use of experimental animals; protocols were approved by the Italian Minister for Scientific
Research and by the San Raffaele Scientific Institutional Animal Care and Use Committee in
accordance with the Italian law.
Genotyping
Mouse genotypes were determined through PCR on genomic DNA purified from tail biopsy.
Biopsies were obtained within the second and the third week of life. Forward PCR primer
sequences: 5’-ACCTAGCCTGCCTGTACTTT for the identification of the null allele, 5’-
GACTGAAGTTACAGATGGTTGTG for the wt allele. Common reverse primer sequence: 5’-
CCACCCTCCAGTTTGGTTTA. The obtained PCR products were: a single band of 450 base
pairs (bp) for theMecp2-null mice; a single band of 400 bp for the wt animals and the two
bands for heterozygous females.
Behavioural analyses
CD1 wt,Mecp2-null andMecp2+/- heterozygous mice were assayed as described by Guy et al
[6]. To avoid any bias, an investigator blind to the genotypes of the tested animals performed
all the analyses. Mouse symptoms were scored according to the following scale [6]: 0 if the
symptom was absent, 1 if the symptom was present but mild, 2 when the symptom was severe.
Mobility, hindlimb clasping, tremor and general condition were the symptoms analysed. To
test mobility, mice were allowed to move freely on the bench; the spontaneity of the movement
was evaluated. Hindlimb clasping was assessed by holding mice by the tail: a score equal to 1
was given to animals showing clasping for more than 3 seconds and equal to 2 when longer
than 10 seconds. Tremor was assessed by placing mice on the palm of a hand. Eventually, the
term “general conditions” refers to the assessment of the integrity of the fur, eye crustiness and
body posture. To be noticed, all animals that either scored “2” during tremor assessment or
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rapidly lost weight were euthanized for ethical reasons. At the experimental endpoint, animals
were euthanized through cervical dislocation after Avertin (Sigma) deep anaesthesia. At the
time of death, the main organs were dissected and weighed.
The cognitive functions were assessed through Novel Object Recognition (NOR) test. The
experimental apparatus used for the NOR test was an open-field box, 43x43x32 cm (Ugo
Basile, Varese, Italy) made of Plexiglas, placed in a dimly illuminated room. Animals per-
formed each test individually. Briefly, each animal was placed in the arena and allowed to
explore two identical, unknown objects for 10 minutes (familiarization phase). 30 minutes
(short-term memory) or 24 hours (long-term memory) after the familiarization phase, mice
were placed again in the same arena containing a new object that replaced one of the two
already tested. During the test phase the time spent exploring the familiar object (Ef) and the
new object (En) was recorded separately by two observers blind to the groups and the discrimi-
nation index was calculated as follows: [(En-Ef)/(En+Ef)] x 100.
qPCR
SymptomaticMecp2-null CD1 animals (P60) andMecp2+/- heterozygous females (P240),
and their wt siblings were deeply anesthetized with Avertin (Sigma) and sacrificed through cer-
vical dislocation. Cortices from 11 wt, 9Mecp2-null males, 8Mecp2+/- heterozygous and 9 wt
females were dissected and total RNA was purified using the RNeasy Mini Kit (QIAGEN),
after mechanical trituration of the tissue using a glass-glass potter. RNA was then retro-tran-
scribed using commercial kits (Qiagen). qPCR reactions were run using the following primers:
BDNF (Fwd 5’-AAGTCTGCATTACATTCCTCGA, Rev 5’-TTATCAATTCACAATTAAAG
CAGCAT), HIF1α (Fwd 5’-CCCAGTGAGAAAAGGGAAAG Rev 5’-ATTTGACGGATGAG
GAATGG), Mecp2 (Fwd 5’-AAACCACCTAAGAAGCCCAAAT, Rev 5’-TTGACAAACAAGT
TTCCCAGGG), 18S (Fwd 5’-GTAACCCGTTGAACCCCATT, Rev 5’-CCATCCAATCGGTAG
TAGCG). RNA levels were normalized to the 18S internal standard and expressed as percentage
of the wt (considered as 100%) ± SEM.
Western blot
Asymptomatic/early symptomatic (P30, n = 4), symptomatic (P60, n = 5)Mecp2-null CD1,
symptomatic (P240, n = 7)Mecp2+/- female animals and their wt siblings (n = at least 3) were
deeply anesthetized with Avertin (Sigma) and sacrificed. Cortices were dissected and mechani-
cally triturated with a glass-glass potter. Proteins were extracted on ice in lysis buffer (Tris-
HCl pH 7,4 50 mM, NaCl 200 mM, Triton 1%, EDTA 2 mM, DTT 1 mM, Protease Inhibitor
(Roche) and phosSTOP (Roche)). Samples were then sonicated and centrifuged for 15 min.
After centrifugation, the supernatant was collected and proteins quantified (Bicinchoninic
Acid Assay, Thermo Scientific). Equal amounts of proteins were loaded on SDS-PAGE and
blotted onto nitrocellulose; after blocking, nitrocellulose membranes were incubated overnight
with the following primary antibody: anti-S6 ribosomal protein (1:1000, Cell Signaling), anti-
phospho S6 ribosomal protein 240–244 (1:1000, Cell Signaling), anti-GAPDH (1:1000, Ther-
moFisher) and anti-Mecp2 (1:1000, Cell Signaling). After washing, filters were incubated with
HRP-conjugated secondary antibody (1:10000, Sigma) and positive signals visualized through
chemiluminescence (Thermo Scientific). The obtained films were scanned and analysed using
ImageJ. Protein levels were expressed as percentage of the wt (considered as 100%) ± SEM.
Histological analyses
P60 brains were dissected out, grossly cut in serial 3 mm thick sections and fixed in Carnoy’s
solution (70% EtOH, 20% CHCl3, 10% Acetic Acid) before inclusion in paraffin. 4 μm thick
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coronal sections produced by microtome slicing of frontal cortical areas from 6 wt and 4 null
animals were used for DAPI staining (Invitrogen). Nuclear size and cell density were measured
using ImageJ.
Blood tests
Blood samples were collected from deeply anaesthetized animals (6 wt and 4 ko) that were
soon after euthanized to collect tissues for histological analyses. Blood samples were allowed to
coagulate at room temperature and then centrifuged to collect the serum. Samples were stored
at -20°C for further analyses. Chemical analyses were performed with the ILab Aries analyser
(Instrumentation Laboratory, Werfen group, Milan, Italy). Total serum cholesterol and triglyc-
erides were measured using kits and controls supplied by ILab.
Results and Discussion
C57BL/6 (from now on abbreviated with B6) heterozygousMecp2tm1.1Bird females were crossed
with CD1 wt male mice (Crl:CD1 (ICR); Charles River) and the progeny backcrossed for 10
generations (detailed in Materials and Methods). As expected [10], CD1Mecp2-null males are
infertile.
The first advantage we observed is the duplication of the number of pups per litter (the aver-
age pups per litter is roughly five in B6 and nine in CD1), thus obviously increasing the number
of null and heterozygous animals obtained from a single litter (Fig 1A). In a time window of
one year, the B6 colony exhibited a 33% frequency of cannibalized litters; on the contrary, in
the CD1 colony cannibalism resulted only occasional, with an estimated frequency of less than
3%. Moreover, in the majority of the cases, CD1 heterozygous females take better care of their
pups, provided that pregnant females are not disturbed immediately before and after delivery.
Jugloff et al. [15] demonstrated that in the B6 colony the number of animals inheriting the
null allele (null males and heterozygous females) per litter is under the expected frequency of
50%. Our B6 colony partially reproduces this observation; in fact, we found a reduced, although
not statistically significant, number of animals bearing the null allele (p = 0,09; Chi square = 2,79
d.f. = 1; Fig 1B). In the CD1 colony the percentage of animals bearing the null allele is roughly
50% and both the heterozygous females and the null males are normally represented (p = 0,5;
Chi square = 0,46; d.f. = 1; Fig 1C).
To evaluate if CD1Mecp2-null mice present the same general alterations reported in the B6
null animals, mice were observed every week starting from post-natal day 20 (P20) [6] (Fig 2).
Apart from some expected variability, after roughly one month of life, almost all the CD1 null
animals showed tremors (Fig 2A). In the same time window, spontaneous movements and
mobility begun to diminish and, at 6 weeks of age, all the tested animals displayed mobility
impairments (Fig 2B). Hind limb clasping appeared a later and milder phenotype compared to
tremors and altered mobility. Indeed, it became evident only at around 7–8 weeks of life and
only 60% of CD1 null animals displayed it throughout life (Fig 2C). CD1 heterozygous females
show a similar, although shifted in time, progression of phenotypes. Mild symptoms were in
fact detected between 3 to 4 months of life. Tremors (Fig 2A’) and mobility impairments (Fig
2B’) were the first to be detected, while hind limb clasping (Fig 2C’) became obvious between 6
and 7 months. It is reported thatMecp2mouse models on the B6 background develop symp-
toms during the same time window (3–8 weeks for males and after 3 months for females), with
hind limb clasping and breathing abnormalities following the onset of spontaneous movement
issues [10].
Uneven wearing of teeth and misalignment of the jaws are fairly usual in B6 null animals
[10], while they were never noticed in CD1 null animals. After 6–7 weeks of age, CD1 null
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Fig 1. CD1Mecp2tm1.1Bird-/X females have large litters with balancedMecp2 alleles. A: Litters obtained
crossing CD1Mecp2-/X heterozygous females and wt males are larger (an average of 9,13±0,39 pups per
litter) than those from the same crossing in the B6 background (an average of 4,73±0,17 pups per litter). The
percentage of males and females is similar in each litter (roughly 50%) for both the genetic backgrounds. B:
Although not statistically significant, in the B6 litters the frequency of the null allele results slightly lower than
the expected 50%.C: The null allele is normally represented in the CD1 progenies. Statistical significance
was evaluated through Chi-square analysis, significance is considered when p<0,05.
doi:10.1371/journal.pone.0153473.g001
Fig 2. Phenotypic characterization of the CD1Mecp2-null male andMecp2+/- female mice. The presence of symptoms (tremor (A-A’), mobility (B-B’)
and clasping (C-C’)) was evaluated in null (A, B, C) and heterozygous animals (A’, B’, C’) starting from P20. Continuous lines represent the evolution of the
symptomatology, while histograms represent the percentage of null or heterozygous animals displaying the symptom at any given age. Statistical
significance was evaluated through two-way ANOVA, Bonferroni’s post-hoc test: * = p<0,05; ** = p<0,01; *** = p<0,001; **** = p<0,0001; n = 15 wt males,
13Mecp2-null, 7Mecp2+/- and 7 wt females.
doi:10.1371/journal.pone.0153473.g002
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animals are easily distinguishable from their wt littermates as they show ungroomed coat and
hunched stance. The worsening of the general conditions immediately precedes death and
mortality, usually peaks between P70 and P80 (Fig 3). Animals are often euthanized at this age
for ethical reasons due to the presence of severe symptoms, but given the variability in the
severity of symptoms, some animals survive even longer. In rare cases animals become strongly
symptomatic and suddenly die even at earlier ages. In the case ofMecp2+/- females, the worsen-
ing of the animal conditions does not lead to early natural death.
In general, CD1 and B6 mice have different body size, with CD1 animals weighing signifi-
cantly more compared to B6 mice (the average adult CD1 weight is 40 gr, while adult B6 mice
weigh 20 gr). For this reason, handling CD1 animals might be easier in some procedures com-
pared to B6 mice. At P35, the weight of CD1Mecp2-null animals is moderately (although sig-
nificantly) reduced compared to controls but reached wt levels after roughly 6–7 weeks of age
(Fig 4A); on the contrary, B6 null animals are strongly underweighted compared to wt mice
ever since birth [10,23]. Notably, in rare cases a rapid decrease in weight is observed in the
CD1 model.Mecp2 heterozygous females do not show any particular difference in weight com-
pared to wt until 3 months of age, when a progressive increase is observed (Fig 4B).
As previously found in B6Mecp2-null and heterozygous animals and in accordance with
RTT patients, a macroscopic evaluation of organs dissected from symptomatic animals (both
males and females) highlighted a decrease in brain weight [11, 23, 24, 25]. Interestingly, spleen
and liver weights (Fig 5) are reduced in males but not in females.
Although the severity of cognitive alterations is still debated in RTT, many studies demon-
strate that mouse models ofMecp2 diseases are characterized by severe cognitive impairments.
No cognitive data are available for the B6 model; however, reduced freezing time during cued
fear conditioning tests and diminished time spent exploring a novel object (NOR: Novel Object
Recognition test) affect a variety of other RTT mouse models (Mecp2tm1.1jae/Y,Mecp2308,
Mecp2R168X,Mecp2S421A,Mecp2T158A; [26–31]). To assess the presence of cognitive deficits in
short- and long-term memory, CD1 wt andMecp2-null mice were tested with NOR at different
ages (Fig 6).Mecp2-null males showed a significant impairment in short-term memory with
respect to wt already at P28, as stated by the significant reduction of the discrimination index
(144%, t = 8,978; p<0,0001). A greater cognitive impairment was observed when long-term
memory was tested. Indeed, the discrimination index was significantly reduced compared to
wt (235%, t = 6,381; p<0,0001). The cognitive deficit persisted also at P56, when the neurologi-
cal symptoms inMecp2-null animals are fully manifested. In fact, the discrimination index was
significantly reduced in short- and long-memory by 168% (t = 3.860; p = 0.0007) and 203%
(t = 5.940; p<0.0001), respectively.
Next, we investigated whether some typical morphological and molecular alterations dis-
played by differentMecp2-null mice are present also in the CD1 model.
As expected [32], cortical neurons of symptomatic CD1Mecp2-null mice are more densely
packed (Fig 7A, 7A’ and 7B) and exhibit smaller nuclei with respect to wt controls (Fig 7C).
The cerebral cortex of CD1 null animals confirms a reduced transcription of the plasticity
modulator Bdnf [33]. In accordance with previous observations made on the B6Mecp2-null
model [34], we also demonstrate a significant up-regulation of Hif1α transcription in the CD1
null cortex (Fig 8A). The deregulation of this transcript might be due to the reduction of oxy-
gen levels in the blood related to a generalized status of chronic hypoxia, in line with the
common feature of RTT patients suffering from respiratory abnormalities. As expected, in het-
erozygous females the levels of transcription ofMecp2 is reduced of roughly 40%; in these ani-
mals we detected a similar (although not significant) tendency to the reduction in the levels of
Bdnf, but we did not detect any defect in Hif1α expression. Moreover, reduced AKT/mTOR
signalling, originally described in the B6 Jaenisch null animals [35] and then confirmed in
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other cellular and animal models ofMecp2 [23,36], is evident also in the CD1 background. The
level of rpS6 phosphorylation is in fact significantly reduced in both young (P30) and old (P60)
Mecp2-null animals and in old symptomatic (P240) heterozygous females (Fig 8B).
It is known that RTT patients display different metabolic alterations [30]; these impairments
are reproduced in mouse models of the disease depending on their genetic background
[13,21,37,38,39]. Accordingly, the metabolism of peripheral cholesterol (total serum cholesterol,
low-density lipoprotein and triglyceride) is abnormally elevated in the 129Mecp2tm1.1Bird/Y
mouse model at P60, but not in the B6Mecp2tm1.1jae/Y [34].Mecp2tm1.1Bird/Y mice maintained on
a mixed 129S6B6F1 background reveal markedly increased triglycerides levels throughout life
Fig 3. CD1Mecp2-null animals have a life span comparable to that of B6 null animals.CD1 null animals
(red circles) are compared to wt controls (black squares). Arrows represent the timing of appearance of the
different symptoms described in Fig 2 (dotted lines = 50–99% of animals have the given symptom,
continuous line = 100% of the animals have the symptom; n = 18Mecp2-null).
doi:10.1371/journal.pone.0153473.g003
Fig 4. The weight of CD1 null mice is mildly reduced compared to wt while it is altered in
heterozygous females. A: Young CD1 null mice display a subtle reduction of body weight compared to wt
animals. The weight reaches wt levels at around 50 days of age.B: Beginning from three months of age
Mecp2+/- animals result overweighed compared to wt controls. Importantly, Mecp2+/- females do not die
spontaneously, thus the data are based on the day of euthanasia. Statistical significance was evaluated
through two-way ANOVA, Bonferroni’s post-hoc test: * = p<0,05; ** = p<0,01; *** = p<0,001;
**** = p<0,0001; n = 21 wt males, 20 null, 7Mecp2+/- and 7 wt females.
doi:10.1371/journal.pone.0153473.g004
CD1 Background Facilitates MeCP2 Related Studies
PLOS ONE | DOI:10.1371/journal.pone.0153473 April 20, 2016 8 / 14
and increased cholesterol after 6 weeks of age [13], whereas theMecp2tm1.1jae/Y line kept on a
mixed 129SvEV-C57BL6-BALB/c background shows increased serum cholesterol and triglycer-
ides at 7 weeks of age [40]. Our CD1Mecp2tm1.1Bird/Y model show unaltered levels of cholesterol
both in pre- and post-symptomatic stages, but, in line with previous observations, triglycerides
levels are increased at P60 once the symptoms became evident (Fig 8C). Overall these data seem
to suggest that cholesterol levels are more affected than those of triglycerides by modifiers gene
and, consequently, by the genetic background. Therefore, inMecp2-null mice metabolic pheno-
types strongly depend on the genetic background whereas neurological alterations seem to be
less sensitive to genetic modifiers.
Fig 5. Mecp2-null and heterozygous mice display a reduction in the size of specific organs. The weight
of CD1 null organs compared to wt males resulted reduced for brain, spleen and liver.Mecp2+/- females
displayed a reduced brain size and an increase in overall size at the time of sacrifice (the weight of the organs
is represented as percentage of the total body weight of each animal). Statistical significance was evaluated
through Student’s t-test; * = p<0,05; ** = p<0,01; n = 12 wt males, 10 null, 8Mecp2+/- and 9 wt females.
doi:10.1371/journal.pone.0153473.g005
Fig 6. Cognition of CD1Mecp2-null animals is impaired. Cognition of CD1 wt and null animals was tested
with the novel object recognition test. Animals were assayed at P28 (30 wt and 27 null) and P56 (17 wt and 10
null) and displayed strong impairments of both short and long term memory at both ages. Statistical
significance was evaluated through Student’s t-test; *** = p<0,001.
doi:10.1371/journal.pone.0153473.g006
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Conclusions
Mutations inMECP2 cause a broad spectrum of neurological disorders generally characterized
by cognitive deficiencies, motor impairments and seizures. Neurodegeneration is not observed
in mice mimicking MeCP2 disorders or in RTT patients, and phenotypic rescue is possible
uponMecp2 re-activation in animal models [6–9], suggesting that successful therapeutic inter-
vention are possible. However, no effective treatment for RTT syndrome andMECP2-associ-
ated disorders currently exists. The major challenge in the field is therefore the identification of
molecular pathways associated with the pathology that can be targeted with specific treatments.
Such treatments obviously need thorough testing in mouse models ofMecp2 alterations, to
assess their effectiveness in ameliorating the general health condition or specific clinical symp-
toms [36]. Because of that and their vast use in the field,Mecp2-null mouse models hold great
promise for translational research. However, the poor breeding capabilities, the reduced litter
size and the bad health conditions of transgenic animals can represent a serious limiting factor.
It is well known that the phenotype developed byMecp2-deficient animals can vary accord-
ing to the genetic background and, therefore, to its specific set of modifier genes. Previous
Fig 7. Morphological defects featured by CD1Mecp2-null cortices. A, A’: Representation of nuclear
staining (DAPI) in wt andMecp2-null frontal cortical lobes. B: Cell density is increased inMecp2-null cortices
compared to wt samples. Statistical significance was evaluated through Student’s t-test ** = p<0,01; n = 6 wt
and 4 null at P60.C: Nuclear size is reduced inMecp2-null samples stained with DAPI. C’: Kolmogorov-
Smirnov test revealed a maximum distance between the two groups of 7,7%, with a p<0,01; * = p<0,05 post-
hoc Student’s t-test; n = 6 wt and 4 null at P60. (Scale bar: A, A’ 100 μm; a, a’ 50μm).
doi:10.1371/journal.pone.0153473.g007
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publications [13,40] and our present study suggest that this is particular true for metabolic
alterations. Therefore, promising treatments should be tested on more than one mouse model/
strain ofMecp2 [41]. A detailed description of the different features displayed byMecp2 strains
harbouring the same genetic mutation would thus aid investigators in choosing the proper
genetic background for their studies [20].
Here, we demonstrate that, compared to the B6 strain, the novel CD1Mecp2tm1.1Bird strain
presents a higher breeding success and larger litters that would facilitate basic and translational
studies, including heterozygous mice and pregnant females. In our experience these advantages
have so much accelerated our studies, while reducing the number of housed animals and there-
fore the costs, to overwhelm the disadvantage of using an outbred strain that is generally
characterized by increased variability. Moreover, it is worthwhile to remind that because the
molecular defects produced by lack of MeCP2 are often mild in magnitude [5], a high number
of animals is anyhow often necessary to obtain significant data.
The CD1 hemizygousMecp2-null male recapitulates most of the measurable outcomes
described in the B6 background both at the behavioural, cellular and molecular level. Accord-
ingly, this model was already used to highlight maturation defects driven by lack of Mecp2 dur-
ing both embryonic [42] and adult [43] development. In conclusion, we suggest that this novel
mouse strain has a high potential to accelerate and integrate research on Rett syndrome and
MECP2-related pathologies and should be considered as a valid tool for future basic and/or
translational studies.
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Fig 8. CD1Mecp2-null animals largely reproduce previously describedmolecular phenotypes. A: qPCRs comparing the expression of different genes
(BDNF, Hif1α,Mecp2) in CD1 wt or null males (P60), and wt or heterozygous females (P240). Data are expressed as percentage of null or heterozygous
samples versus wt male or female controls (100% ±SEM). (Student’s t-test; * = p<0,05; ** = p<0,01; n = 9 null, 10 wt males, 8 het and 9 wt females). B:
Western blots representing the down-regulation of rpS6 phosphorylation (on serine 240–244) in CD1 null animals at P30 and P60 in males (n = 3 wt and 4
null at P30; n = 5 null and 7 wt at P60) and inMecp2+/- females at P240 (n = 7 wt and 7 heterozygous). Statistical significance was evaluated through
Student’s t-test; * = p<0,05; ** = p<0,01; C: Serum cholesterol and triglycerides levels in slightly and fully symptomatic animals. Statistical significance was
evaluated through Student’s t-test; * = p<0,05; n = 4 wt and 6 null at P30; n = 8 wt and 9 null at P60.
doi:10.1371/journal.pone.0153473.g008
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